Tonix Pharmaceuticals Holding Corp (TNXP)
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research.
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
CHATHAM, NJ / ACCESSWIRE / July 17, 2024 / With the completion of its final pre-NDA meeting with the FDA, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced it is filing an NDA submission in 2H 2024 and laying plans for the commercial launch of Tonmya™* for the management of fibromyalgia, assuming approval by the FDA in 2H 2025. The fibromyalgia market has not seen a new FDA-approved drug in over 15 years.
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling on Thursday after the biopharmaceutical company announced a proposed public offering for its shares. Tonix Pharmaceuticals doesn't have the finer details of this offering ready just yet.
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 40% Today?
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling on Wednesday after the biopharmaceutical company announced a proposed public offering for its shares. Tonix Pharmaceuticals doesn't provide any finer details about this offering.
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 31% Today?
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Monday after the company's shares underwent a reverse stock split this morning. That reverse stock split saw Tonix Pharmaceuticals consolidate 32 shares of TNXP stock into a single share.
